

Corp., Dkt. No. C-2492, 101 F.T.C. 373, 1974 WL 175259, at \*1 (F.T.C. Mar. 9, 1983); see also, e.g., *In the matter of the Readers' Digest Ass'n*, Dkt. No. C-2075, 102 F.T.C. 1268, 1971 WL 128725, at \*2 (F.T.C. Sept. 30, 1983) (concluding that "the public interest requires eliminating" a provision where "the costs that the [provision] imposes on respondent appear to outweigh any consumer benefits [that it] may confer"). Furthermore, the public interest is served by setting aside orders and provisions that restrict constitutionally protected speech where such restrictions "cause[] injury to [respondent] and the public that outweighs any benefit that may be derived from the restriction." *In the Matter of the American College of Obstetricians and Gynecologists*, Dkt. No. C-2855, 104 F.T.C. 524, 1984 WL 565347, at \*1 (F.T.C. Aug. 28, 1984).

Here, the Order should be vacated in its entirety because "the Complaint does not provide even an 'ephemeral possibility[]' of harm, let alone a 'reason to believe' the law has been violated." Dissenting Statement at 2. The fact that the Complaint fails to identify any violation of section 7 "invalidates any justification for the order," *id.* at 6, and confirms that the Order confers no benefit on consumers. In light of the utter lack of justification for the Order, the harm that the Order causes to Mr. Sheffield easily outweighs its nonexistent benefits. See *Readers' Digest Ass'n*, 102 F.T.C. 1268, 1971 WL 128725, at \*2. Furthermore, the only restrictions imposed by the Order—preventing Exxon from appointing Mr. Sheffield or any Pioneer employee to its Board and prohibiting Exxon from appointing Mr. Sheffield to serve as an adviser in any capacity to Exxon's management—"unnecessarily inhibit" Mr. Sheffield, thousands of Pioneer employees, and even Exxon "from engaging in conduct which, in and of itself, is innocuous and may, in certain circumstances, be procompetitive." *In the matter of Occidental Petroleum Corp.*, 101 F.T.C. 373, 1974 WL 175259, at \*1. Vacatur of the Order is warranted to remove these unnecessary restrictions.

The Order "ignored the public interest by using [the FTC's] Complaint to obtain a consent agreement" that specifically targeted Mr. Sheffield, "an individual who was *not* party to the agreement." Dissenting Statement at 1. The public interest is harmed when an individual's constitutional and other legally protected rights are trampled upon by a federal agency without due process or other protections. As outlined in detail in Mr. Sheffield's

Comment, the FTC shared the draft Complaint with Mr. Sheffield only two days before Exxon signed the Consent Order, without ever engaging with Mr. Sheffield's counsel on the allegations in the Complaint. See Ex. 1, Sheffield Comment at 21–22. The "factual failings" of the Complaint are therefore "exacerbated by the process failings that the Majority embraced in this investigation," including the Majority's decision to "hide[] behind the caption that names only Exxon" despite the fact that the Order directly targets Mr. Sheffield, whose name appears "47 times in an eight-page redacted Complaint." Dissenting Statement at 4–5.

In addition to violating Mr. Sheffield's constitutional right to due process, the Order and Complaint disregard Mr. Sheffield's First Amendment rights, leveraging his protected government petitioning to support the FTC's flawed narrative that Mr. Sheffield is a purported advocate for collusion among oil producers, *see id.* at 4–5. Vacatur of the Order is therefore also warranted to protect Mr. Sheffield's constitutional rights to due process and to petition the government for redress. See *In the Matter of the American College of Obstetricians and Gynecologists*, 104 F.T.C. 524, 1984 WL 565347, at \*2 (modifying order to clarify that "this order shall not be construed to prevent [respondent] from . . . [e]xercising rights permitted under the First Amendment to the United States Constitution to petition any federal or state government, executive agency, or legislative body concerning legislation, rules or procedures.").

In light of all of these factors, the Order should be set aside and vacated in its entirety.

Dated: March 14, 2025.

Respectfully submitted,

/s/ David Gelfand

David Gelfand,

Jeremy Calsyn,

*Cleary Gottlieb Steen & Hamilton LLP, 2112 Pennsylvania Avenue NW, Washington, DC 20037, 202-974-1522, Counsel for Scott Sheffield.*

[FR Doc. 2025-06562 Filed 4-16-25; 8:45 am]

**BILLING CODE 6750-01-P**

## GENERAL SERVICES ADMINISTRATION

[Notice—MA—2025—05; Docket No. 2025-0002; Sequence No. 3]

### Federal Management Regulation (FMR); Rescinding FMR Bulletin B-2023-55

**AGENCY:** Office of Government-wide Policy (OGP), General Services Administration (GSA).

**ACTION:** Notice of rescission of FMR Bulletin B-2023-55.

**SUMMARY:** GSA is issuing a notice to rescind Federal Management Regulation (FMR) Bulletin B-2023-55, "Fleet Management Information Systems" dated May 19, 2023 due to recent Executive orders.

**DATES:** *Applicability date:* April 17, 2025.

**FOR FURTHER INFORMATION CONTACT:** For clarification of content please contact Mr. Alexander J. Kurien, Deputy Associate Administrator, Office of Government-wide Policy, Office of Asset and Transportation Management, at 202-495-9628 or by email at [vehicle.policy@gsa.gov](mailto:vehicle.policy@gsa.gov).

#### SUPPLEMENTARY INFORMATION:

##### Background

GSA is rescinding FMR Bulletin B-2023-55 in line with Executive Orders (E.O.) 14148, *Initial Rescissions of Harmful Executive Orders and Actions*, dated January 20, 2025, and E.O. 14154, *Unleashing American Energy*, dated January 20, 2025, which revoked E.O. 14057, *Catalyzing Clean Energy Industries and Jobs Through Federal Sustainability*, dated December 8, 2021.

##### Larry Allen,

*Associate Administrator, Office of Government-wide Policy.*

[FR Doc. 2025-06582 Filed 4-16-25; 8:45 am]

**BILLING CODE 6820-14-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Minority Health and Health Disparities; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Institute on Minority Health and Health Disparities Special Emphasis Panel, June 18, 2025, 9:00 a.m. to June 18, 2025, 6:00 p.m., National Institutes of Health, NIMHD, DEM II, Suite 800, 6707 Democracy Boulevard, Bethesda, MD 20892 which

was published in the **Federal Register** on April 9, 2025, FR Doc 2025–06088, 90 FR 15256.

This meeting notice is to cancel the meeting scheduled June 18, 2025. This meeting will not be rescheduled.

Dated: April 11, 2025.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–06486 Filed 4–16–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; FFRDC Review Meeting.

*Date:* May 9, 2025.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Address:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W530, Rockville, Maryland 20850.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Shamala K. Srinivas, Ph.D., Associate Director, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Rockville, Maryland 20850, 240–276–6442, [ss537t@nih.gov](mailto:ss537t@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 11, 2025.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–06556 Filed 4–16–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Minority Health and Health Disparities; Amended Notice of Partially Closed Meeting

Notice is hereby given of a change in the meeting of the National Advisory Council on Minority Health and Health Disparities, May 06, 2025, 10:00 a.m. to May 06, 2025, 05:30 p.m., National Institutes of Health, 31 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on March 31, 2025, FR Doc 2025–05511, 90 FR 14270.

This meeting notice is being amended to change the meeting format from hybrid to virtual. The meeting is partially Closed to the public.

Dated: April 11, 2025.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–06488 Filed 4–16–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation

**AGENCY:** National Institutes of Health, National Institute of Allergy and Infectious Diseases.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Cambridge Enterprise Limited, University of Cambridge, located in Cambridge, United Kingdom, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before May 2, 2025 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Wade Green, Ph.D., Acting Branch Chief, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852–9804, phone number 301–761–7505, or [wade.green@nih.gov](mailto:wade.green@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following represents the intellectual property to be licensed under the prospective agreement: European Patent Application Patent Application No. EP23386021.2, filed March 10, 2023, titled “Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation” (HHS Reference No. E–266–2023–0–EP–01) and International Patent Application No. PCT/EP2024/056247, filed on March 8, 2024, titled “Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation” (HHS Reference No. E–266–2023–0–PC–01). All rights in these inventions have been assigned to Cambridge Enterprise Limited and the Government of the United States of America.

The prospective patent license will be for the purpose of consolidating patent rights with Cambridge Enterprise Limited, the co-owner of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective patent license will be exclusive, and may be limited to those fields of use commensurate in scope with the patent rights. It will be sublicensable, and any sublicenses granted by Cambridge Enterprise Limited in the United Kingdom will be subject to the provisions of 37 CFR part 404.

The subject patent rights pertain to devices and methods for single-cell electroporation of human cells for clinical uses. Specifically, this subject invention describes certain conductive polymer electrodes that have properties that may allow for their use in the development of microfluidic-based electroporation devices for clinical uses.